

Department für Kleintiere und Pferde der
Veterinärmedizinischen Universität Wien
Klinische Abteilung für Interne Medizin Pferde
(Leitung: Univ.-Prof. Dr. med. vet. Jessika-M. Cavalleri, Dipl. ECEIM)

Equine Parvovirus-Hepatitis Screening in Horses and Donkeys with Histopathologic Liver Abnormalities

**Vorkommen von Equinem Parvovirus – Hepatitis bei Pferden und Eseln mit
histopathologischen Leberveränderungen**

zur Erlangung der Würde einer
DOCTOR MEDICINAE VETERINARIAE
der Veterinärmedizinischen Universität Wien

vorgelegt von
Mag. med. vet. Verena Zehetner, Dipl. ECEIM

Wien, im Oktober 2022

Erstbetreuerin: Univ.-Prof. Dr. med. vet. Jessika-M. Cavalleri, Dipl. ECEIM
Klinische Abteilung für Interne Medizin Pferde
Department für Kleintiere und Pferde
Veterinärmedizinische Universität Wien

Zweitbetreuer: Univ.-Prof. Dr. med. vet. Herbert Weissenböck, Dipl. ECPHM
Institut für Pathologie
Department für Pathobiologie
Veterinärmedizinische Universität Wien

Gutachter: Prof. Dr. Katharina L. Lohmann, PhD, Dip. ACVIM/ECEIM
Klinik für Pferde
Veterinärmedizinische Fakultät
Universität Leipzig

INHALTSVERZEICHNIS

1.	Einleitung und Zielsetzung	4
2.	Publikation	7
3.	Diskussion	23
4.	Zusammenfassung	27
5.	Summary	29
6.	Abkürzungsverzeichnis	30
7.	Literaturverzeichnis	31
8.	Danksagung	35

1. Einleitung und Zielsetzung

Die Theiler's Disease, auch equine Serumhepatitis genannt, ist eine akut verlaufende Hepatitis mit Leberzellnekrosen, welche in einem Leberversagen enden kann. Es existiert keine spezifische Behandlungsmöglichkeit, erkrankte Pferde können nur symptomatisch therapiert werden. Die Theiler's Disease wurde erstmals 1918 von Sir Arnold Theiler beschrieben, nachdem es während Impfstudien in Südafrika zur Vorbeugung der Afrikanischen Pferdepest (African Horse Sickness) nach der Verabreichung von equinem Antiserum zu schweren akuten Hepatitiden und Leberversagen bei mehreren Pferden kam (Theiler 1918). Seitdem wurde die Erkrankung weltweit festgestellt und steht meist im Zusammenhang mit der vorherigen Verabreichung von aus Pferden stammenden biologischen Produkten wie equinem Plasma, Tetanus- und Botulismus-Antitoxin, Antiserum gegen *Streptococcus equi* und allogenen Stammzellen (Aleman et al. 2005; Chandriani et al. 2013; Divers et al. 2018; Guglick et al. 1995; Hjerpe 1964; Kopper et al. 2020; Messer und Johnson 1994a; Messer und Johnson 1994b; Panciera 1969; Step et al. 1991; Theiler 1918; Thomsett 1971; Tomlinson et al. 2019a), jedoch gibt es auch Berichte von erkrankten Pferden, welche zuvor keine Blutprodukte erhielten oder nur in Kontakt mit infizierten Tieren standen (Theiler 1918; Tomlinson et al. 2019a; Tomlinson et al. 2019b). Lange Zeit wurde aus diesem Grund eine infektiöse Ursache als Auslöser der Erkrankung vermutet, aber erst vor Kurzem richtete sich der Fokus auf ein bis dato unbekanntes Virus als potenziellen Erreger der Theiler's Disease (Divers et al. 2018).

Im Jahr 2018 wurde erstmals das equine Parvovirus-Hepatitis (EqPV-H) aus Serum- und Leberproben eines an der Theiler's Disease erkrankten und verstorbenen Pferdes isoliert (Divers et al. 2018). Auch in diesem Fall wurde dem Pferd vor Ausbruch der Krankheit Tetanus-Antitoxin verabreicht, ein biologisches Blutprodukt, produziert aus Pferdeserum (Divers et al. 2018). Bei EqPV-H handelt es sich um ein einzelsträngiges DNA-Virus mit Kapsid und kleinem Genom, welches der Spezies *Ungulate Copiparvovirus 6*, Genus *Copiparvoviridae* (Familie *Parvoviridae*) zugeordnet wird (Divers et al. 2018). Seit seiner Entdeckung konnte EqPV-H mit der Ausnahme eines Falles in allen anderen an der Theiler's Disease erkrankten Tiere nachgewiesen werden (Baird et al. 2020; Divers et al. 2018; Kopper et al. 2020; Ramsauer et al. 2021; Tomlinson et al. 2019a; Tomlinson et al. 2019b; Vengust et al. 2020).

Mehrere Studien zeigen eine weltweite Verbreitung des Virus, die EqPV-H DNA Prävalenz liegt hier bei klinisch gesunden, subklinisch infizierten Pferdepopulationen in den USA, China, Südkorea, Brasilien, Österreich und Deutschland zwischen 4,4% – 17% (Altan et al. 2019; Badenhorst et al. 2021; Divers et al. 2018; Lee et al. 2021; Lu et al. 2018; Lu et al. 2020;

Meister et al. 2019b; Moraes et al. 2021) und die Seroprävalenz bei 15 – 34,7% (Badenhorst et al. 2021; Divers et al. 2018; Meister et al. 2019b). In Betrieben mit kürzlich aufgetretenen Fällen equiner Serumhepatitis in den USA und Kanada stieg die DNA-Prävalenz auf 54-62% an (Baird et al. 2020; Tomlinson et al. 2019b; Tomlinson et al. 2020). Nicht alle DNA-positiven Pferde sind jedoch klinisch erkrankt, nur bei wenigen Tieren kommt es zu einem letalen Verlauf. In den meisten Fällen zeigt sich keine Symptomatik einer Lebererkrankung, subklinische Hepatitiden mit erhöhten Leberenzymen sind jedoch beschrieben (Badenhorst et al. 2021; Baird et al. 2020; Chandriani et al. 2013; Lu et al. 2020; Tomlinson et al. 2019b).

Des Weiteren konnten in 61,1% kommerzieller equiner Serumprodukte stammend aus Neuseeland, den USA, Kanada, Italien und Deutschland EqPV-H DNA nachgewiesen werden, in 77,8% der untersuchten Produkte waren Antikörper gegen EqPV-H vorhanden (Meister et al. 2019a). Dies spricht für eine weltweite Zirkulation des Virus in der Pferdepopulation, was ebenso von wirtschaftlichem Interesse ist, da eine EqPV-H-Kontamination kommerziell erhältlicher biologischer Produkte ein bedeutendes Risiko für die Verbreitung des Virus darstellt.

Vengust et al. (2020) publizierten die ersten vier Fälle EqPV-H assoziierter Theiler's Disease in Europa. Die Pferde stammten aus demselben Betrieb in Slowenien und mussten aufgrund von Leberversagen euthanasiert werden, das Virus konnte dabei in Leberproben aller erkrankten Pferde nachgewiesen werden (Vengust et al. 2020).

Die klinischen Anzeichen reichen von Ikterus, Apathie, Inappetenz bis zu neurologischen Symptomen wie Blindheit, Kopfpresen und Ataxie (Baird et al. 2020; Chandriani et al. 2013; Divers et al. 2018; Kopper et al. 2020; Tomlinson et al. 2019a; Tomlinson et al. 2019b; Tomlinson et al. 2020; Vengust et al. 2020). Der Verlauf ist oft letal und erkrankte Pferde müssen aus Mangel an therapeutischen Optionen euthanasiert werden (Baird et al. 2020; Divers et al. 2018; Tomlinson et al. 2019a; Tomlinson et al. 2019b; Vengust et al. 2020). Bei infizierten Pferden sind leberspezifische biochemische Parameter wie Gamma-Glutamyl Transferase (GGT), Aspartate Aminotransferase (AST), Sorbitol Dehydrogenase (SDH), Glutamate Dehydrogenase (GLDH), Alkalische Phosphatase (ALP), Alanine Aminotransferase (ALT), Bilirubin, Gallensäuren und Ammoniak häufig erhöht (Baird et al. 2020; Kopper et al. 2020; Ramsauer et al. 2021; Tomlinson et al. 2019a; Tomlinson et al. 2019b; Vengust et al. 2020).

In post-mortem-Untersuchungen stellten sich die Lebern erkrankter Tiere atrophisch, abgeflacht, brüchig und mit veränderter Farbe dar (Kopper et al. 2020; Tomlinson et al. 2019a; Vengust et al. 2020), histopathologisch konnten hepatozelluläre Nekrosen, ein Untergang der lobulären Architektur sowie lymphozytäre Infiltrationen beobachtet werden (Divers et al. 2018;

Kopper et al. 2020; Tomlinson et al. 2019a; Tomlinson et al. 2019b; Tomlinson et al. 2020; Vengust et al. 2020).

Bei experimentell infizierten Pferden zeigte sich ein Höhepunkt der Virämie ungefähr fünf Wochen nach Infektion, die höchsten Viruslasten wurden im Serum und der Leber gefunden (Tomlinson et al. 2020). Auch in weiteren Organen und Körperflüssigkeiten konnte EqPV-H DNA nachgewiesen werden, die Viruslasten waren hier jedoch deutlich niedriger (Tomlinson et al. 2020). Selbst 15 Wochen nach Infektion konnte in den meisten Geweben weiterhin virale DNA detektiert werden (Tomlinson et al. 2020). Der Beginn der Hepatitis wurde in dieser Studie im Zeitraum der Serokonversion und Abnahme der Virämie beobachtet.

Zusammenfassend gaben mehrere Studien der letzten Jahre einen deutlichen Hinweis darauf, dass EqPV-H der Auslöser der Theiler's Disease sein könnte, jedoch blieb die Frage offen, ob das Virus auch im Zusammenhang mit anderen Lebererkrankungen bei Equiden steht.

Durch den nachgewiesenen Lebertropismus von EqPV-H ist seine Beteiligung an weiteren Hepatopathien denkbar und möglich, dies wurde jedoch noch nicht näher erforscht.

Ziel dieser Doktorarbeit war, das Vorkommen sowie die Viruslast von EqPV-H in Lebern von Pferden und Eseln mit histopathologischen Auffälligkeiten, mit Ausnahme der Theiler's Disease, zu evaluieren, um dessen Einfluss auf unterschiedliche Hepatopathien abschätzen zu können und einen möglichen Zusammenhang mit weiteren Lebererkrankungen aufzuzeigen.

2. Publikation

Equine Parvovirus-Hepatitis Screening in Horses and Donkeys with Histopathologic Liver Abnormalities

Zehetner, V., Cavalleri, J. V., Klang, A., Hofer, M., Preining, I., Steinborn, R., & Ramsauer, A. S. (2021). Equine Parvovirus-Hepatitis Screening in Horses and Donkeys with Histopathologic Liver Abnormalities. *Viruses*, 13(8), 1599. <https://doi.org/10.3390/v13081599>

Article

Equine Parvovirus-Hepatitis Screening in Horses and Donkeys with Histopathologic Liver Abnormalities

Verena Zehetner ¹, Jessika-M. V. Cavalleri ^{1,*}, Andrea Klang ², Martin Hofer ³, Irina Preining ¹, Ralf Steinborn ³ and Anna S. Ramsauer ¹

¹ Internal Medicine, University Equine Clinic, University of Veterinary Medicine, 1210 Vienna, Austria; verena.zehetner@vetmeduni.ac.at (V.Z.); irina.preining@vetmeduni.ac.at (I.P.); sophie.ramsauer@vetmeduni.ac.at (A.S.R.)

² Department for Pathobiology, Institute of Pathology, University of Veterinary Medicine, 1210 Vienna, Austria; andrea.klang@vetmeduni.ac.at

³ Genomics Core Facility, VetCore, University of Veterinary Medicine, 1210 Vienna, Austria; Martin.hofer@vetmeduni.ac.at (M.H.); Ralf.steinborn@vetmeduni.ac.at (R.S.)

* Correspondence: Jessika.cavalleri@vetmeduni.ac.at

Abstract: There is strong evidence that equine parvovirus-hepatitis (EqPV-H) is associated with the onset of Theiler's disease, an acute hepatic necrosis, in horses. However, the impact of this virus on other hepatopathies remains unknown. The objective of this retrospective study was to evaluate the prevalence and quantify the viral loads of EqPV-H in formalin-fixed, paraffin-embedded equine and donkey livers with various histopathologic abnormalities. The pathologies included cirrhosis, circulatory disorders of the liver, toxic and metabolic hepatic diseases as well as neoplastic and inflammatory diseases ($n = 84$). Eight normal liver samples were included for comparison as controls. EqPV-H DNA was qualitatively and quantitatively measured by real-time PCR and digital PCR, respectively. The virus was detected in two livers originating from horses diagnosed with abdominal neoplasia and liver metastasis (loads of 5×10^3 and 9.5×10^3 genome equivalents per million cells). The amount of viral nucleic acids measured indicates chronic infection or persistence of EqPV-H, which might have been facilitated by the neoplastic disease. In summary, this study did not provide evidence for EqPV-H being involved in hepatopathies other than Theiler's disease.

Keywords: EqPV-H; hepatopathy; neoplasia; hepatitis; horse; *ungulate copiparvovirus 6*



Citation: Zehetner, V.; Cavalleri, J.-M.V.; Klang, A.; Hofer, M.; Preining, I.; Steinborn, R.; Ramsauer, A.S. Equine Parvovirus-Hepatitis Screening in Horses and Donkeys with Histopathologic Liver Abnormalities. *Viruses* **2021**, *13*, 1599. <https://doi.org/10.3390/v13081599>

Academic Editor: Romain Paillot

Received: 10 July 2021

Accepted: 4 August 2021

Published: 12 August 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Theiler's disease, also known as equine serum hepatitis, is an acute and potentially life-threatening fulminant hepatic necrosis. The disease was first reported by Sir Arnold Theiler in 1918 in South Africa, when horses developed severe acute hepatitis and fulminant liver failure after administration of convalescent equine antiserum during vaccination studies to prevent African horse sickness. Affected livers were characterised by severe centrilobular hepatic necrosis [1]. Since then, Theiler's disease has been reported in many countries worldwide and has been mostly associated with prior administration of equine-origin biologic products such as equine plasma, tetanus and botulism antitoxins, antiserum against *Streptococcus equi* and allogenic stem cells [1–8]. Nevertheless, there have been reported cases of Theiler's disease, which did not receive any equine biologic products and in horses that were in contact with affected horses [1,9,10]. These incidences implied that an infectious and transmissible pathogen might be the cause for the development of Theiler's disease, but a causative agent was not detected for many years [11].

In 2018, Divers et al. detected an unknown virus in serum and liver samples obtained from a horse that died of Theiler's disease after receiving tetanus antitoxin [8]. The newly recognised virus was named equine parvovirus-hepatitis (EqPV-H). It harbours a small single-stranded DNA genome and is assigned to the species *Ungulate Copiparvovirus 6*,

genus *Copiparvoviridae* (*Parvoviridae* family) [8,11]. EqPV-H has been detected in all but one of the recently reported cases of Theiler's disease and has therefore been linked to the onset of the disease [7–10,12,13]. In Europe, viral loads of 1.26×10^4 to 2.04×10^9 genome equivalents (GE)/million cells were detected in liver tissue of four horses suffering from Theiler's disease [13]. In healthy horses in the USA, China, Germany and Austria a DNA prevalence for EqPV-H has been reported between 7% and 17% [8,14–18] compared to a markedly higher DNA prevalence between 54% and 79% in farms in the USA and Canada with recently documented cases of Theiler's disease [10,12,19]. Current research is focused on disease outbreaks, possible transmission and seroprevalence in horse populations.

In experimentally infected horses a peak viraemia approximately five weeks after infection was observed. The highest viral load was found in serum and liver, which indicates hepatotropism [19]. Lower amounts of viral DNA were also detectable in various other organs and body fluids. As late as 15 weeks after infection, EqPV-H was still detectable in the majority of tissues tested [19]. The onset of hepatitis has been linked to seroconversion and a decrease in viraemia, which further supports the hypothesis of EqPV-H as the causative agent for this disease [19].

All recent findings suggest that EqPV-H is associated with Theiler's disease. However, there are no studies available so far that were designed to answer the question, whether the hepatotropic EqPV-H might also be associated with other hepatic diseases. Therefore, the aim of this retrospective study was to evaluate the occurrence and to determine the load of EqPV-H in livers of horses and donkeys showing histopathologic abnormalities other than Theiler's disease.

2. Materials and Methods

2.1. Sample Collection and Histopathologic Evaluation

The samples archive of the Institute of Pathology was searched for horses and donkeys that were euthanised between 2003 and 2019 at the University Equine Hospital of the Vetmeduni Vienna with various liver pathologies. All available histopathologically abnormal formalin-fixed, paraffin-embedded tissue (FFPE) samples were included in this study. In addition, randomly selected liver samples with normal histopathology served as controls. Initial histopathologic examination was performed following euthanasia of the horse or donkey as part of the histopathological work-up of the patient. To improve standardisation of this study, samples were independently re-evaluated by an experienced pathologist.

Tissue slides were stained with haematoxylin and eosin and categorised into seven groups based on histopathologic evaluation (group 1: primary and secondary neoplastic diseases, group 2: inflammatory diseases, group 3: cirrhosis, group 4: circulatory disorders of the liver, group 5: toxic and metabolic hepatic diseases, group 6: multiple diseases, and group 7: normal liver tissue). Neoplastic diseases (group 1) included primary neoplasia of the liver or bile ducts as well as secondary neoplasia and tumour-like lesions. The inflammatory diseases (group 2) comprised leucocytic inflammatory cell infiltration of hepatic parenchyma and biliary tract. Cirrhosis (group 3) was characterised by nodular parenchymal regeneration together with fibrosis and consequential disruption of the liver architecture. Circulatory disorders of the liver (group 4) predominantly included cases of subacute and chronic liver congestion. Toxic and metabolic hepatic diseases (group 5) were defined as degenerative processes with reversible and irreversible cytopathology of hepatocytes such as lipidosis, amyloidosis and vacuolation. Samples that were diagnosed with more than one of the stated histopathologic abnormalities were assigned to group 6. Group 7 comprised normal tissue samples.

2.2. Detection of EqPV-H by Real-Time PCR

Viral nucleic acid was extracted from $10 \times 10 \mu\text{m}$ paraffin-embedded liver specimens using QIAamp[®] DNA Micro Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Extracts were stored at -20°C until further analysis. Viral load of EqPV-H was related to cell number using *TTC17*, a gene that exists in mammalian species at a

single copy per haploid nuclear genome. The single-copy calibrator gene was selected from a catalogue that uses various databases and available genomic data to intuitively determine single-copy orthologs between different phylogenetic groups and species [20]. The EqPV-H assay was designed according to all published EqPV-H complete coding sequence variants from USA, China and Austria to date, and a single-stranded oligonucleotide containing the EqPV-H target sequence was used as positive control. Information regarding the oligonucleotide sequences of the assays and the EqPV-H positive control are provided in Table 1.

Table 1. Detection and quantification assays (real-time PCR and digital PCR) for measurement of cellular EqPV-H load.

Assay	GenBank Identity	5' to 3' Sequence of Oligonucleotide	Amplicon Size (bp)
EqPV-H *	NC_040652.1, MG136722.1, MH500787.1 to MH500792.1, MN218583.1 to MN218592.1, MW256660.1 to MW256663.1	F: AAG ATA TGC CGC CAT TTG AA R: CTG AAA AGG CAT TCC GTC AG P: FAM-CAG AGA AAT /ZEN/ CCT GAG CGG TGG CCT-IBFQ PC: ATC TTC TAT <u>AAA GAT ATG CCG CCA TTT GAA AAG GCC</u> <u>ACC GCT CAG GAT TTC TCT GAC TAT TAT</u> <u>GTT TCT GAC GGA ATG CCT TTT CAG ACT</u> TTG TAT G	77
		F: CTG GAC AAC AGC CAT GAC AAA R: AAG TCT AAG GGC ATC TGA GTC CC P: FAM-CAC AGG GTC /ZEN/ CTC CTC TGC TCC TGTC-IBFQ	147

F: forward primer, R: reverse primer, P: probe, PC: positive control (amplified region is under-lined) * Designed against all publicly available EqPV-H variants FAM: 6-fluorescein amidite, ZEN: internal quencher inserted after 9th base of the ZEN™ Dual-Quenched Probe; IBFQ: Iowa Black™ Fluorescent Quencher. Synthesis of oligonucleotides: Integrated DNA Technologies, Leuven, Belgium.

Real-time PCR was performed in a volume of 15 µL composed of 1 × PCR buffer B2 (Tris-HCl, (NH₄)₂SO₄ and Tween 20; Solis Biodyne, Tartu, Estonia), 3.5 mM MgCl₂, 200 µM of each dNTP (Solis Biodyne), 250 nM of each primer and 200 nM hydrolysis probe (Integrated DNA Technologies, Leuven, Belgium), 1 U HOT FIREPol® DNA polymerase (Solis Biodyne) and 3 µL template DNA. Cycling conditions consisted of an initial 15-min incubation at 95 °C for polymerase activation and template denaturation followed by 45 amplification cycles (denaturation: 95 °C for 15 s, annealing/elongation: 60 °C for 60 s). Real-time PCR was run on the qTOWER3/G Real-Time PCR Thermal Cycler operated by the software qPCRsoft384 (v1.2.3.0) (Analytic Jena, Jena, Germany). Experimental samples were measured in triplicate. Equine DNA served as positive control for the *TTC17* assay. Contamination was monitored by a no-template control. A standard deviation threshold of less than 0.4 was adopted for the *C_q* values of the technical triplicates. In case of a higher standard deviation, the replicate that deviated the most from the mean was excluded.

To generate a standard curve for the EqPV-H real-time PCR assay, sequential dilutions of a synthetic oligonucleotide were amplified. The parameters of the resulting regression line facilitated determination of the assay's amplification efficiency as well as the detection limit and helped to adjust the amount of template DNA for subsequent quantitative measurement based on digital PCR (Figure 1). Furthermore, monitoring based on real-time PCR was performed for additional organs available from positive cases.




Figure 1. Viral loads of samples #1 and #2 matched the quantitative dynamic range of the assay. The standard curve was obtained by plotting the *Cq* values of serial standard dilutions against the decadic logarithm of the respective copy-number concentration. *r*: Pearson's correlation coefficient.

2.3. Quantification of Cellular Viral Load Using Digital PCR

Digital PCR was performed in Sapphire chips on the Naica Crystal Digital™ PCR System (Stilla Technologies, Villejuif, France). The mastermix contained 1 × PerfeCTa Multiplex qPCR ToughMix (Quanta Bio, Beverly, USA) with 100 nM fluorescein, 800 nM of each primer and 250 nM hydrolysis probe for each target (*TTC17* and *EqPH-V*) and 9 μL template. Following droplet generation, amplification was carried out according to the following protocol: 95 °C for 10 min, 45 cycles of 95 °C for 10 s and 60 °C for 40 s. Endpoint fluorescence values measured on the Naica Prism 3 reader were analysed by Crystal Miner software (v. 2.4.0.3; Stilla Technologies, Villejuif, France). The software's standard settings were applied to export the copy numbers for the two targets.

3. Results

3.1. Clinical Records and Histopathologic Evaluation of Liver Samples

The study population comprised 87 horses and 5 donkeys. Clinical records included age, breed and sex of the animals, clinical diagnosis, activity of plasma liver enzymes and liver-associated blood-biochemical parameters, as well as the primary cause for euthanasia and histopathologic liver findings (Table A1). Clinical diagnosis of liver disease was the cause for euthanasia in 27 cases. In the remaining patients, liver abnormalities were an incidental finding at necropsy and horses were euthanised for unrelated reasons. Nine out of 17 liver samples initially assessed as unremarkable, were found to be histopathologically abnormal in the second review performed during the course of this study.

Based on histopathologic evaluation, the 92 liver samples included in the study were assigned to the following seven groups: neoplastic diseases ($n = 20$, group 1), inflammatory diseases ($n = 24$, group 2), cirrhosis ($n = 5$, group 3), circulatory disorders of the liver ($n = 4$, group 4), toxic and metabolic hepatic diseases ($n = 14$, group 5), multiple diseases ($n = 17$, group 6) and normal liver tissue ($n = 8$, group 7). Samples that were assigned to group 6 were simultaneously diagnosed with at least two histopathologic features of groups 1 to 5 and were predominantly associated with inflammatory disorders (Table A1).

3.2. Virus Detection by Real-Time PCR and Copy Number Quantification by Digital PCR

From the study cohort ($n = 92$), two EqPV-H-positive livers were identified by real-time PCR. Both belonged to group 1 comprising neoplastic disease specimens. The samples, hereafter referred to as samples #1 and #2, produced *Cq* values at the upper end of the quantitative dynamic range (29.96 ± 0.20 and 30.08 ± 0.34 , respectively; Figure 1). Copy number measurement by digital PCR (Figure 2) determined EqPV-H genome equivalents per million cells of 5×10^3 and 9.5×10^3 (samples #1 and #2, respectively; Table 2). Additional organs available from the two horses included heart, lung, spleen and intestine

of case #1 and intestine of case #2. Real-time PCR detected a very low amount of viral DNA in these tissues. In detail, C_q values at or beyond the limit of quantification were determined for heart, lung, spleen and intestine of case #1 (32.58 ± 0.46 , 33.57 ± 1.22 , 32.62 ± 1.15 and 34.62 , respectively) and the intestine of case #2 (35.23).




Figure 2. Detection of EqPV-H (A) and the cellular calibrator gene *TTC17* (B) by dPCR in liver samples #1 and #2. Each panel represents a separate experimental chamber on a chip where the reaction mix containing DNA from liver samples (1:20 dilution for *TTC17*) was segregated into individual droplets and assessed for the presence of EqPV-H and *TTC17*. •: positive samples; ●: negative signals, respectively. The blue line designates the arbitrary fluorescence threshold separating the signals from background.

Table 2. Digital PCR determination of cellular viral load.

Sample	TTC17 Copies/ μ L (1:20 Dilution)	EqPV-H Copies/ μ L	Cellular Viral Load	
			Virus/Cells	GE/ 10^6 Cells
#1	151.5 ± 6.1	7.54 ± 1.81	1/201	5.0×10^3
#2	78.4 ± 4.7	7.46 ± 1.42	1/105	9.5×10^3

For each of the two intestines, only for one of the three technical replicates a real-time PCR signal was obtained. This indicated that the amount of virus in the sample was at the detection limit of the assay.

3.3. Clinical History and Pathological Findings of Horses with EqPV-H Positive Liver Tissue

3.3.1. Case #1

A 21-year-old Warmblood gelding was referred to the University Equine Hospital of the Vetmeduni Vienna due to acute colic and anorexia. The gelding was in good body condition. Clinical examination revealed an elevated heart and respiratory rate (heart rate: 64 beats/min; respiratory rate: 44 breaths/min), mildly elevated rectal temperature ($38.1 \text{ }^\circ\text{C}$), prolonged capillary refill time and diminished gastrointestinal sounds. De-

pendent peripheral oedema of the distal extremities and ventral abdominal oedema were present. The following plasma liver enzymes and liver associated blood-biochemical parameters were measured in this case and were within normal limits: glutamate-dehydrogenase, gamma-glutamyltransferase, triglycerides and total protein. Albumin concentration was reduced (14.1 g/L, reference range: 24 to 45 g/L). Diagnostic workup was highly suspicious for abdominal neoplasia and the horse was euthanised. On necropsy severe ascites and a whitish, firm, indistinctly circumscribed mass with the dimensions of approximately 5 cm × 5 cm × 15 cm was found which was located between stomach and spleen as well as multiple, similar, nodular masses, up to 6 mm in diameter. Masses were attached to the serosa of the abdominal cavity and visceral serosa of liver, spleen and intestine, within the liver and spleen parenchyma and the perirenal fat. Histologic examination of these masses revealed well differentiated epithelial tumour cells arranged in tubules with mucus secretion, surrounded by intensive desmoplasia (Figure 3A). In some locations metaplastic ossification of the stromal tissue was also evident. The single-layered, cuboidal to columnar, mucus-secreting tumour cells were bearing hyperchromatic, round or ovoid, basal oriented nuclei (Figure 3B). Mitotic figures were present in low numbers. On histopathology, the masses were diagnosed as ductal adenocarcinoma with stromal osseous metaplasia and transcoelomic peritoneal metastases. The masses most probably derived from the intestinal mucosa.




Figure 3. (A,B). Histology of liver sample #1: Adenocarcinoma metastases. (A): Sharply demarcated infiltration of epithelial tumour cells arranged in tubules surrounded by intensive desmoplasia. Mucus secretion can be seen within the tubules; bar = 400 µm. (B): Single-layered tumour cells containing round or ovoid, basal oriented nuclei (B); bar = 80 µm.

3.3.2. Case #2

A 19-year-old Warmblood gelding was referred to the University Equine Hospital of the Vetmeduni Vienna for further evaluation of elevated liver enzyme activities and weight loss. On clinical examination the horse was lethargic, in poor body condition, normothermic, normocardic and had a physiologic respiratory rate and effort, reddened mucous membranes, diminished gastrointestinal sounds and a left-sided holodiastolic heart murmur. Measurement of liver specific plasma enzyme activities detected an elevation of gamma-glutamyl transferase (132 U/L, reference range: <30 U/L), glutamate dehydrogenase (20.08 U/L, reference range: <13 U/L) and aspartate-aminotransferase (619 U/L, reference range: <550 U/L).

Transcutaneous abdominal ultrasound revealed hepatomegaly, with the liver being detectable from the 5th to the 13th intercostal space on the left side of the abdomen. Liver tissue had an heterogeneous patchy appearance with hyperechoic areas. Multiple rounded, hyperechogenic, not well-circumscribed and partly vascularised masses of various sizes were detectable within the liver parenchyma (Figure 4). Ultrasonographic findings were highly indicative of liver neoplasia. The owners decided against further diagnostics and opted for euthanasia. Pathological examination detected multiple nodular, firm and whitish-grey, masses of various sizes up to 20 cm in diameter in the liver parenchyma. One

white, firm, nodular mass with a diameter of 2 cm was found in the lung parenchyma. Another such mass of 10 cm in diameter was found in the mesocolon. The other organs were unremarkable. Histologic examination of these masses revealed that they were comprised of malignant, mesenchymal cells separated by collagenous stroma (Figure 5A), arranged in a pericapillar and perivascular whorling pattern (Figure 5B). Mitotic figures were not detected within 10 high-power fields and cellular pleomorphism was low. The tumour cells immunohistochemically displayed expression of smooth muscle actin and some of them additionally demonstrated desmin-antigen-reactivity. On the basis of the perivascular pattern and expression of contractile proteins, the tumour was diagnosed as metastasising perivascular wall tumour.




Figure 4. Ultrasonographic image of mass within liver parenchyma. Ultrasonographic image obtained from the right 14th intercostal space of the abdomen at the costochondral border. Liver tissue is highly inhomogeneous with a rounded, hyperechoic and weakly circumscribed mass within the liver parenchyma (×: dorso-ventral expansion of the mass).




Figure 5. (A,B). Histology of liver sample #2: Perivascular wall tumour. (A): The masses found in the liver were comprised of malignant, mesenchymal spindle cells, separated by collagenous stroma; bar = 400 μm . (B): The tumour cells are arranged in a pericapillar and perivascular whorling pattern, bar = 80 μm .

4. Discussion

Recently, strong evidence has been presented indicating that EqPV-H is the causative agent for the onset of Theiler's disease [7–10,13]. In human medicine, viral infection is one of the most common causes for hepatitis. Reported hepatotropic viruses include hepatitis A, B, C, D and E virus, but also non-hepatotropic viruses such as adenovirus, cytomegalovirus and herpes simplex virus can lead to acute hepatitis and fulminant hepatic failure [21,22]. Depending on the infectious agent and the degree of severity of the disease, histopathologic findings may include signs of acute or chronic hepatitis, liver cirrhosis, congestion and even

hepatocellular carcinoma formation [21,22]. As human hepatopathy-associated viruses can lead to widespread manifestations, the determination of the influence of the hepatotropic EqPV-H on other liver diseases in equids beside Theiler's disease and subclinical hepatitis was the main focus of this investigation.

Our cohort consisted of 8 normal equine livers and 84 horse/donkey livers with various hepatopathies. Only in 2/92 formalin-fixed paraffin-embedded (FFPE) liver sample EqPV-H DNA was detectable. Both positive cases were diagnosed with abdominal neoplasia and liver metastasis. The general weakness and immunosuppression that accompany neoplastic disease may possibly facilitate secondary infection with EqPV-H. In humans, cancer is associated with a higher susceptibility to opportunistic infections [23], which may also be the case in equine patients. Further studies in humans have demonstrated that the immune response was disrupted with different tumour types and reduced T-cell activation during viral or bacterial infection has been detected in mice [24]. Thus, EqPV-H may not only infect horses suffering from neoplastic disease more easily, but also, persistence of the virus may be supported or even benefit from an insufficient immune response. Further research is warranted in order to test this hypothesis, as only two livers tested positive for EqPV-H in this study and therefore cannot provide sufficient evidence.

In human medicine, a few viruses are associated with the onset of tumours. Regarding the liver, chronic infections with hepatitis B and C viruses can lead to hepatocellular carcinoma [25]. The question as to whether EqPV-H could potentially be the inciting cause for the development of primary liver tumours in equids was not the objective of this study and needs to be evaluated by further research. In our study, both samples that tested positive for EqPV-H were from horses diagnosed with secondary liver neoplasia. Only two primary liver neoplasms were included in group 1, and both of these cases that were diagnosed as adenocarcinoma of the biliary ducts were negative for the presence of EqPV-H. The remaining samples of group 1 were diagnosed with metastases in the liver, while the primary neoplasia originated from lymphoma, hamartoma, carcinoma, round cell neoplasia, leukaemia, hemangiosarcoma, adenocarcinoma, squamous cell carcinoma and spindle cell carcinoma (Table A1).

Case #1 suffered from a ductal adenocarcinoma with metastases in multiple abdominal organs, including the liver parenchyma. As liver enzymes were within normal limits, acute EqPV-H infection was not suspected, and the presence of EqPV-H seemed to be either a co-occurrence or a contributing factor of this horse's disease. Very low amounts of EqPV-H could also be detected in the tissue of the spleen, where tumour metastasis was present, as well as in heart and lung tissue of this horse. This is similar to the findings of Tomlinson et al. [19], in which EqPV-H DNA was detected in several other tissues (lung, spleen, kidney, heart and intestine) in addition to the liver. As in our study, of all the infected tissues, the highest viral load was found in the liver, further supporting the hepatotropism of this virus. Persistence of the virus was suspected by Tomlinson et al., since viral DNA was still detected in serum, liver, lung, spleen, bone marrow and other tissues 15 weeks after experimental infection [19]. In analogy, human parvovirus B19 can persist in serum and tissues for up to years after infection [26–28]. Here, we provide further evidence for the persistence of EqPV-H in the liver and other organs, supported by an absence of acute infection in combination with a low concentration of cellular viral DNA. Earlier studies have detected EqPV-H DNA in serum samples originating from clinically normal horses that were in contact with the horses diagnosed with EqPV-H-associated Theiler's disease [10,12]. Whether the case presented here might have suffered from unrecognised hepatitis prior to hospitalisation cannot be determined retrospectively, however, an acute infection seemed unlikely, as glutamate dehydrogenase and gamma-glutamyl transferase levels were within normal limits in the serum.

Case #2 was referred due to an elevation in liver specific enzyme activities and ongoing weight loss. Metastasising perivascular wall tumour was diagnosed on histopathology. Smooth muscle cells of the colonic wall were suspected as the origin of the neoplasia. Furthermore, neoplastic cells were noted infiltrating the liver parenchyma. In this case,

only liver and colon samples were stored and available for this study, and EqPV-H was only detected in the liver tissue. Increased liver specific enzymes can be explained by the infiltration of liver tissue by neoplastic cells and the resulting damage and cell loss of liver parenchyma. There was no evidence of inflammation on histopathologic evaluation. Thus, persistence of the virus in liver tissue or low-grade chronic infection of the horse seems possible.

Recently, viral loads ranging from 1.26×10^4 GE/million cells to 2.04×10^9 GE/million cells were reported for FFPE liver samples obtained from four horses suffering from Theiler's disease [13]. The diagnosis was based on clinical signs, serum biochemistry changes and histopathologic findings [13]. In our study, the two liver samples that were clearly positive for EqPV-H nucleic acid had viral loads of 5×10^3 and 9.5×10^3 GE/million cells. The viral loads in these two cases were slightly lower than previously described for acutely infected horses by Vengust et al. [13], which could be another indication of a chronic infection. This is in line with the study of Tomlinson et al. reporting viral loads of 1×10^4 to 1×10^5 in liver tissue 5 weeks after experimental infection [19]. Viraemia developed within a median time period of 2.3 weeks after inoculation of the virus. After 6.5 weeks, eight out of ten horses developed hepatitis, which was defined as two liver enzymes having values above the reference range [19]. One horse also suffered from clinical signs including icterus, mild lethargy and inappetence [19]. After 15 weeks, viral loads of 1×10^1 to 1×10^5 GE/million cells were still detectable in the liver which again highlights the possibility that EqPV-H infection can become chronic with persistence of the virus [19], as was assumed in our two cases, which exhibited low amounts of the virus.

A limitation of this study was the storage of tissue until analysis, which might have had an influence on measured viral loads. As the study was performed retrospectively, all tissue samples were stored embedded in paraffin between 1 and 17 years at room temperature, which could have affected the amount of detectable virus. The two positive samples derived from horses euthanised in the year 2018 had been stored for two years until analysis. Even though storage might have impaired the amount of viral DNA, EqPV-H was successfully detected by the newly designed RT-PCR assay in two livers.

Another interesting fact is that both positive cases were presented to the University Equine Hospital of the Vetmeduni Vienna in the year 2018 with only one month apart from each other in February and March, respectively. This might only be a coincidental finding. An infection during hospitalisation seems unlikely as the incubation period is approximately 4 to 13 weeks, and both patients were euthanised soon after admission (case #1: after 3 days, case #2: at the day of admission). Seasonal occurrence of EqPV-H-associated Theiler's disease during late summer to early fall months has been reported [10,12,13], but the exact time and season of infection in the presented cases cannot be determined retrospectively. Badenhorst et al. [15] reported an EqPV-H DNA prevalence of 8.9% in sera of healthy Austrian horses which is similar to the results of other surveillance studies [8,14–18]. Therefore, a considerably higher risk of infection in Austrian horses seems unlikely.

5. Summary

Although this study is limited by the number of positive samples and the retrospective study design, the results did not find an association between EqPV-H and other liver diseases apart from Theiler's disease, as in 82/84 liver samples with histopathologic abnormalities, no EqPV-H viral DNA was detectable. Nevertheless, the fact that both positive samples were detected in the group of 20 horses with neoplastic disease is interesting and future investigations of a potential association or even interaction between EqPV-H infection and neoplastic disease may be warranted.

Author Contributions: Conceptualisation, V.Z., J.-M.V.C. and A.S.R.; data curation, V.Z., A.K., M.H., I.P., R.S. and A.S.R.; formal analysis, A.K., M.H., I.P., R.S. and A.S.R.; funding acquisition, V.Z., J.-M.V.C. and A.S.R.; investigation, V.Z. and I.P.; methodology, V.Z., M.H. and A.S.R.; project administration, J.-M.V.C. and A.S.R.; software, M.H. and R.S.; supervision, J.-M.V.C. and A.S.R.;

writing—original draft, V.Z.; writing—review and editing, J.-M.V.C., A.K., M.H., R.S. and A.S.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research project was funded by the Foundation PRO Pferd, Switzerland (PR 2020-11).

Institutional Review Board Statement: Not applicable. No experimental animals were used in this study. Samples were selected from horses euthanised at the University Equine Hospital of the Vetmeduni Vienna due to medical conditions unrelated to this retrospective study. Owners gave their permission to use the samples for research purpose.

Informed Consent Statement: Owners of all euthanised horses involved in the study signed a written consent to use tissue material for research purposes.

Data Availability Statement: Data is contained within the article.

Acknowledgments: We would like to thank all members of the Institute of Pathology from the University of Veterinary Medicine Vienna, especially Herbert Weissenböck, Christiane Weissenbacher-Lang, Sandra Högl, Julia Matt, Antonia Geyer, Nora Nedorost and Karin Fragner for their support and contribution to this manuscript. Open Access publication was partially funded by Open Access Funding by the University of Veterinary Medicine.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Table A1. Group classification, clinical records and histology findings of liver samples.

S #	G 1	G 2	G 3	G 4	G 5	G 6	G 7	Age	Sex	Breed	Clinical Diagnosis	Histology Liver	GGT < 30 U/L	AST < 550 U/L	BA < 20 μmol/L	GLDH < 13.00 U/L	AP < 250 U/L	BIL 0.7-3.1 mg/dL	NH3 < 40 μmol/L	ALB 2.4-4.5 g/dL	TG < 50.0 mg/dL	TP 5.5-7.5 g/dL
1	x							21	M	Warmblood	Abdominal neoplasia	Adenocarcinoma	13	x	x	3.07	x	x	x	1.1	28.0	6.89
2	x							19	M	Warmblood	Liver neoplasia, cholelithiasis	Perivascular wall tumour	132	619	6	20.08	x	x	<LOD	3.75	x	7.44
3	x							20	M	Holsteiner	Colonic impaction, peritonitis, ventricular tachycardia	Adenocarcinoma biliary ducts	x	x	x	x	x	x	x	x	x	x
4	x							20	M	Haflinger	Renal failure, neoplasia suspected	Lymphoma	27	556	x	8.06	171	x	x	2.90	x	8.09
5	x							16	M	Warmblood	Colon displacement, malabsorption syndrome	Vascular hamartoma	20	x	x	116.60	109	x	x	3.46	x	6.58
6	x							21	F	Warmblood	Peritonitis	Carcinoma metastasis in liver	18	x	x	70.99	x	x	x	3.14	x	7.56
7	x							25	M	Warmblood	Hyperlipaemia, anaemia	Undifferentiated round cell neoplasia (myeloid leukaemia suspected)	x	x	x	x	x	x	x	x	709.0	x
8	x							3	M	Thoroughbred	Liquidothorax (neoplasia suspected)	Multicentric lymphoma	x	x	x	x	x	x	x	x	x	x
9	x							22	F	Warmblood	Leukaemia	Lymphatic T-cell leukaemia	30	245	5	145	651	0.90	x	2.69	134.0	5.23
10	x							22	F	Haflinger	Haemothorax (neoplasia suspected)	Haemangiosarcoma metastasis in liver	x	x	x	x	x	x	x	x	x	x
11	x							22	M	Warmblood	Colon tympany, colon displacement	Adenocarcinoma metastasis in liver	x	x	x	x	x	x	x	x	x	x
12	x							7	F	Warmblood	Liquidothorax, ascites (neoplasia suspected)	Adenocarcinoma metastasis in liver	x	x	x	x	x	x	x	2.64	x	6.07
13	x							25	M	Fjord Horse	Spinal ataxia, kidney mass (neoplasia suspected)	Haemangiosarcoma metastasis in liver	x	x	x	x	x	x	x	x	x	8.06
14	x							11	F	Warmblood	Paraneoplastic syndrome	Lymphoma	47	x	27	5.67	x	x	x	3.06	x	7.48
15	x							24	F	Haflinger	Liver failure, immune mediated haemolytic anaemia and thrombocytopenia	Myeloid leukaemia	741	889	162	107.43	1558	9.83	97	2.42	442.0	6.35
16	x							24	M	Standardbred	Haemoperitoneum (lymphoma suspected)	Lymphoma	31	x	x	2.09	x	x	x	2.54	x	6.90
17	x							26	F	Icelandic Horse Mix	Hepatopathy, hepatocerebrohepatopathy	Adenocarcinoma, liver infiltration	332	449	33	77.03	1120	x	116	1.97	252.0	9.48
18	x							32	F	Haflinger	Liquidothorax (neoplasia suspected)	Spindle cell carcinoma, liver metastasis	x	x	x	x	x	x	x	x	x	x
19	x							25	F	Warmblood	Haemoperitoneum	Lymphomoliver infiltration	x	x	x	x	x	x	x	2.00	x	x

Table A1. Cont.

S #	G 1	G 2	G 3	G 4	G 5	G 6	G 7	Age	Sex	Breed	Clinical Diagnosis	Histology Liver	GGT < 30 U/L	AST < 550 U/L	BA < 20 μmol/L	GLDH < 13.00 U/L	AP < 250 U/L	BIL 0.7-3.1 mg/dL	NH3 < 40 μmol/L	ALB 2.4-4.5 g/dL	TG < 50.0 mg/dL	TP 5.5-7.5 g/dL
20	x							24	F	Pony	Theriac/ abdominal neoplasia	Haemangiosarcoma metastasis in liver	x	x	x	x	x	x	x	2.27	x	x
21		x						21	M	Warmblood	Ventricular tachycardia	Chronic eosinophilic granulomatous hepatitis	20	x	x	9.01	213	2.26	x	2.18	466.0	6.82
22		x						6	M	Welsh Pony	Ileus	Acute purulent cholangitis and necrotising hepatitis	x	x	x	x	x	x	x	x	x	x
23		x						5	M	Noriker	Retropharyngeal mass	Acute predominantly non purulent hepatitis	17	x	x	1.29	x	x	x	2.94	31.0	7.58
24		x						18	F	Haflinger	Inflammatory bowel disease, protein losing enteropathy	Chronic purulent hepatitis	93	x	x	6.59	x	x	x	1.65	104.0	6.49
25		x						2	M	Shetland Pony	Shock, tachycardia (gastric rupture suspected)	Acute purulent necrotising hepatitis	x	x	x	x	x	x	x	x	x	x
26		x						1	F	Morgan Horse	Hepatopathy	Acute purulent necrotising hepatitis	x	3036	x	271.72	x	x	47	2.74	59.0	4.81
27		x						15	F	Shetland Pony	Liver neoplasia, hepatocerebrohepatopathy	Chronic purulent abscessing hepatitis	x	x	x	x	x	x	x	x	x	x
28		x						1	M	Warmblood	Septic peritonitis	Acute non purulent hepatitis, cholangitis	x	x	x	x	x	x	x	x	x	9.10
29		x						1 m	M	Warmblood	Pneumonia	Acute purulent necrotising hepatitis	x	x	x	x	x	x	x	x	x	x
30		x						10	M	Standardbred	Morbus maculosus	Acute necrotising lymphoproliferative hepatitis	x	x	x	x	x	x	x	x	x	x
31		x						13	M	Shire Horse	Typhlocolitis, hepatopathy	Acute (partially) purulent hepatitis	54	x	37	37.22	x	6.33	7	3.12	x	8.33
32		x						19	F	Donkey	Luminitis, bronchitis, hepatopathy, hyperlipaemia	Chronic granulomatous hepatitis, interstitial fibrosis	73	564	6	19.87	x	x	7	2.33	284.0	7.01
33		x						13	M	Warmblood	Endocarditis, purulent meningitis	Acute (partially) purulent hepatitis	21	275	4	1.17	196	2.96	x	2.90	x	7.49
34		x						23	M	Icelandic Horse	Adhesions between jejunum and mesenterium, peritonitis, sepsis	Acute necrotising hepatitis	42	x	x	67.18	x	x	x	2.18	646.0	4.40
35		x						8	F	Shetland Pony	Ataxia, dysphagia	Acute necrotising hepatitis	x	x	x	x	x	x	x	x	x	x

Table A1. Cont.

S #	G 1	G 2	G 3	G 4	G 5	G 6	G 7	Age	Sex	Breed	Clinical Diagnosis	Histology Liver	GGT Tc 30 U/L	AST < 550 U/L	BA < 20 µmol/L	GLDH < 13.00 U/L	AP < 250 U/L	BLI 0.7-3.1 mg/dL	NH3 < 40 µmol/L	ALB 2.4-4.5 g/dL	TG < 50.0 mg/dL	TP 5.5-7.5 g/dL
36		x						20	M	Arabian	Neoplasia (equine melanocytic pulmonary fibrosis suspected)	Acute non purulent hepatitis	25	x	x	2.41	x	x	x	2.41	62.0	8.17
37		x						2	F	Icelandic Horse	Intoxication	Acute purulent necrotising hepatitis	x	x	x	x	x	x	x	x	x	x
38		x						16	M	Warmblood	Gastric rupture	Acute purulent serositis	x	x	x	x	x	x	x	x	x	x
39		x						9	F	Shetland Pony	Right dorsal colitis	Acute non purulent hepatitis	33	x	x	74.99	x	x	x	1.07	148.0	2.96
40		x						4	F	Pony	Renal failure	Acute non purulent hepatitis	x	x	x	x	x	x	x	x	72.0	x
41		x						22	F	Welsh Pony	Choke, aspiration pneumonia	Acute non purulent hepatitis	x	x	x	x	x	x	x	1.66	370.0	x
42		x						25	M	Warmblood	Anaemia, thrombocytopenia, immune mediated vasculitis	Acute eosinophilic hepatitis	20	x	4	18.35	x	x	x	2.55	x	8.63
43		x						20	M	Icelandic Horse	Masses neck and sinuses	Chronic eosinophilic granulomatous hepatitis	x	x	x	x	x	x	x	x	x	7.09
44		x						16	M	Noriker	Gastric rupture, peritonitis	Acute purulent serositis	x	x	x	x	x	x	x	x	x	x
45			x					13	F	Warmblood	Hepatoencephalopathy	Cirrhosis	148	4650	x	35.44	665	x	x	2.33	31.0	7.57
46			x					7	F	Hallinger	Hepatoencephalopathy	Cirrhosis	1309	x	x	83.71	x	x	x	x	x	9.25
47			x					7	F	Warmblood	Left dorsal displacement, colonic impaction, hepatopathy	Cirrhosis	139	x	x	532.30	x	x	x	3.59	48.0	8.11
48			x					30	F	Pony	Laminitis, right dorsal colitis, hepatopathy, PPFD	Biliary cirrhosis	163	x	18	63.36	x	x	16	2.32	420.0	5.50
49			x					20	F	Arabian	Hepatoencephalopathy	Cirrhosis	x	x	x	x	x	x	x	x	x	x
50				x				17	M	Warmblood	Cardiogenic shock, atrial fibrillation, ventricular tachycardia	Portal and central vein fibrosis, subacute liver congestion	x	x	x	x	x	x	x	x	x	x
51				x				20	F	Shetland Pony	Colon impaction, liver rupture	Liver haemorrhage	86	x	15	76.07	877	1.63	x	3.03	1308.0	7.50
52				x				12	F	Warmblood	Acute renal failure, septic pericarditis, right heart failure	Subacute liver congestion	21	x	x	7.64	x	x	x	1.79	x	6.56
53				x				2 m	M	Hallinger	Cardiac cushion defect, atrial septum defect, hepatomegaly	Subacute liver congestion	x	x	x	x	x	x	x	x	x	x
54					x			14	M	Standardbred	Gastric neoplasia, multiple cardiac valve insufficiencies	Amyloidosis	24	x	x	1.19	160	0.71	x	2.43	12.0	7.12
55					x			4	F	Miniature Donkey	Hyperlipaemia	Hepatic lipidosis	49	x	x	22.40	x	x	<1.0D	1.80	1748.0	x

Table A1. Cont.

S #	G 1	G 2	G 3	G 4	G 5	G 6	G 7	Age	Sex	Breed	Clinical Diagnosis	Histology Liver	GGT Tc 30 U/L	AST < 550 U/L	BA < 20 µmol/L	GLDH < 13.00 U/L	AP < 250 U/L	BLI 0.7-3.1 mg/dL	NH3 < 40 µmol/L	ALB 2.4-4.5 g/dL	TG < 50.0 mg/dL	TP 5.5-7.5 g/dL
56					x			12	F	Icelandic Horse	Enterocolitis, hepatoencephalopathy	Hepatic lipidosis	96	x	x	95.30	x	x	152	2.14	x	5.38
57				x				10	M	Shetland Pony	Shock, recumbency	Hepatic lipidosis	x	x	x	x	x	x	x	x	x	x
58				x				12	M	Pony	Enterol hyperammonaemia, encephalopathy	Hepatic lipidosis	17	x	x	1.83	x	x	194	2.90	x	5.32
59				x				14	M	Noriker	Weakness, recumbency	Severe siderosis	11	1130	x	7.06	x	x	x	2.82	x	5.49
60				x				15	F	Icelandic Horse	Hyperlipaemia	Hepatic lipidosis	3319	3331	300	590.72	x	2.60	46	3.78	2410.0	7.46
61				x				12	F	Icelandic Horse	Hyperlipaemia	Hepatic lipidosis	x	x	x	x	x	x	x	x	4725.0	x
62				x				16	F	Icelandic Horse	Quadriplegia	Hepatic lipidosis	x	x	x	x	x	x	x	x	x	x
63					x			24	M	Donkey	Paralytic ileus, renal failure, hyperlipaemia, encephalopathy	Hepatic lipidosis, chronic granulomatous hepatitis	x	x	x	x	x	x	x	x	x	x
64					x			10	F	Friesian	Paralytic ileus, endotoxaemia, acute renal failure, hyperammonaemia	Hepatic lipidosis	17	x	x	10.15	x	x	217	1.67	1311.0	4.67
65				x				31	M	Warmblood	Colon impaction, hypotriglyceridaemia	Liver sclerosis, hepatic lipidosis	x	x	x	x	x	x	x	2.96	481.0	6.79
66				x				15	M	Icelandic Horse	Hyperlipaemia	Hepatic lipidosis	73	x	54	117.18	x	1.01	12	2.69	2588.0	6.69
67				x				14	M	Donkey	Hyperlipaemia	Hepatic lipidosis	251	x	10	11.86	x	x	7	3.28	7600.0	5.33
68		o			o	x		20	M	Warmblood	Colitis, malabsorption syndrome	Amyloidosis, acute purulent hepatitis and pericholangitis	42	x	x	2.83	x	x	x	0.78	331.0	4.33
69		o		o		x		5	M	Friesian	Ventricular tachycardia, myocarditis	Subacute liver congestion, centrilobular liver necrosis	43	621	x	67.74	x	x	x	2.69	59.0	5.64
70		o			o	x		7	M	Friesian	Colitis, chronic kidney failure, ventricular tachycardia	Hepatic lipidosis and liver necrosis, acute non purulent hepatitis	34	x	x	42.36	x	x	x	2.55	x	4.68
71		o		o		x		2	M	Quarter Horse	Pleural effusion, ascites (neoplasia suspected)	Subacute to chronic liver congestion, acute non purulent hepatitis	12	364	x	3.21	x	1.90	x	1.67	37.0	5.89
72		o			o	x		23	F	Shetland Pony	Hyperlipaemia	Hepatic lipidosis, acute non purulent hepatitis	x	x	x	x	x	x	x	x	801.0	x
73		o			o	x		13	F	Donkey	Hyperlipaemia	Hepatic lipidosis, acute purulent hepatitis	97	x	14	27.49	476	0.40	x	2.80	1931.0	6.45

Table A1. Cont.

S #	G 1	G 2	G 3	G 4	G 5	G 6	G 7	Age	Sex	Breed	Clinical Diagnosis	Histology Liver	GGT 't < 30 U/L	AST < 350 U/L	BA < 20 μmol/L	GLDH < 13.00 U/L	AP < 250 U/L	BIL 0.7–3.1 mg/dL	NH3 < 40 μmol/L	ALB 2.4–4.5 g/dL	TG < 50.0 mg/dL	TP 5.5–7.5 g/dL
74		o	o				x	17	F	Hafflinger	Protein losing enteropathy, inflammatory bowel disease	Cirrhosis, chronic purulent cholangitis and pericholangitis	37	351	3	34.32	x	x	x	1.21	x	4.48
75	o			o			x	20	M	Thoroughbred	Delayed gastric emptying, hepatopathy (neoplasia suspected)	Squamous cell carcinoma, subacute to chronic liver congestion	175	509	12	348.40	627	3.80	x	2.84	262.0	6.71
76	o	o		o			x	31	M	Warmblood	Paraneoplastic syndrome	Undifferentiated round cell neoplasia, subacute liver congestion, acute non purulent hepatitis	32	351	x	17.54	244	x	x	2.10	x	7.35
77		o		o			x	24	F	Warmblood	Ileus, colon displacement	Subacute liver congestion, focal acute non purulent hepatitis	x	x	x	x	x	x	x	x	x	x
78	o	o	o				x	13	M	Pony	Ascites (neoplasia suspected)	Adenocarcinoma metastasis, acute non purulent hepatitis	x	x	x	x	x	x	x	x	x	7.73
79		o		o			x	6	F	Quarter Horse	Epicolic foramen entrapment, ileus, hyperlipaemia	Hepatic lipidosis, acute non purulent hepatitis	9	x	x	18.27	x	x	x	2.15	548.0	3.78
80	o		o		o		x	16	F	Fjord Horse	Gastric distension, hyperammonaemia, hepabupathy	Carcinoma of biliary ducts, hepatic lipidosis, cirrhosis	55	x	29	13.64	x	x	140	3.11	153.0	7.67
81		o	o				x	15	F	Warmblood	Hepatopathy, hyperlipaemia, PPID	Cirrhosis, acute purulent hepatitis	881	1265	135	217.11	2488	3.54	10	2.69	413.0	8.93
82	o	o					x	12	M	Warmblood	Multicentric lymphoma	Multicentric lymphoma - liver infiltration, chronic lymphoplasmocytic to eosinophilic hepatitis	13	x	x	0.98	x	x	x	1.91	x	8.99
83		o		o			x	4	F	Warmblood	Equine grass sickness suspected	Acute (partially) purulent hepatitis and chronic pericholangitis	x	x	x	x	x	x	x	x	x	x
84		o	o				x	3	F	Arabian	Aspiration pneumonia, liquidothorax	Hepatic lipidosis	x	x	x	x	x	x	x	x	x	x
85							x	8	M	Warmblood	Encephalitis	Unremarkable	8	x	60	1.93	x	x	<LOD	2.98	41.0	7.79
86							x	14	M	Pura Raza Meropuina	Typhlocolitis, liquidothorax	Unremarkable	21	x	x	6.45	157	x	103	2.00	149.0	5.23
87							x	4	M	Warmblood	Chronic renal failure	Unremarkable	x	x	x	x	x	x	x	x	x	x

Table A1. Cont.

S #	G 1	G 2	G 3	G 4	G 5	G 6	G 7	Age	Sex	Breed	Clinical Diagnosis	Histology Liver	GGT 't < 30 U/L	AST < 350 U/L	BA < 20 μmol/L	GLDH < 13.00 U/L	AP < 250 U/L	BIL 0.7–3.1 mg/dL	NH3 < 40 μmol/L	ALB 2.4–4.5 g/dL	TG < 50.0 mg/dL	TP 5.5–7.5 g/dL
88							x	2	F	Warmblood	Mediastinal mass (lymphoma suspected)	Unremarkable	x	x	x	x	x	x	x	x	x	x
89							x	12	M	Icelandic Horse	Renal failure	Unremarkable	15	x	x	44.40	x	x	x	2.55	255.0	5.49
90							x	6	M	Arabian-Paint	Peritonitis	Unremarkable	x	x	x	x	x	x	x	x	x	x
91							x	15	M	Thoroughbred	Haemoperitoneum	Unremarkable	4	x	1	5.07	x	x	<LOD	1.90	x	2.94
92							x	20	F	Trakehner	Gastritis, colon impaction, PPID	Unremarkable	26	230	x	11.21	334	5.63	<LOD	2.77	48.0	7.01
T	20	24	5	4	14	17	8															

Assigned histopathologic groups of liver samples according to their pathologies. Group 1: neoplastic diseases, group 2: inflammatory diseases, group 3: cirrhosis, group 4: circulatory disorders of the liver, group 5: toxic and metabolic hepatic diseases and group 6: multiple diseases. Group 7 included liver samples without pathologies. Group 6 consisted of samples with histopathologic findings of multiple diseases, as in total, 17 samples could be listed in two or even three groups simultaneously. For all samples assigned to Group 6, o marks the histopathologic features of the different groups that were present. Only two primary liver neoplasias were included in this study (# 3 and #80). The clinical records including sex, age and breed of the horse as well as available liver associated blood values are listed for each sample, where blue/red indicates a de- or increase below or above the reference value, respectively. (S#: sample number, G: group, T: total amount, m: months, M: male, F: female, PPID = pituitary pars intermedia dysfunction, GGT: gamma-glutamyl transferase, AST: aspartate transaminase, BA: bile acids, GLDH: glutamate dehydrogenase, AP: alkaline phosphatase, BIL: bilirubin, NH3: ammonia, ALB: albumin, TG: triglycerides, TP: total protein, <LOD: below limit of detection).

References

1. Theiler, A. *Acute Liver-Atrophy and Parenchymatous Hepatitis in Horses*; Union of South Africa. Dept. of Agriculture. 5th and 6th Repts. of the Director of Veterinary Research, 1918; pp. 7–165.
2. Thomsett, L.R. Acute Hepatic Failure in the Horse. *Equine Veter. J.* **1971**, *3*, 15–19. [[CrossRef](#)]
3. Guglick, M.A.; MacAllister, C.G.; Ely, R.W.; Edwards, W.C. Hepatic disease associated with administration of tetanus antitoxin in eight horses. *J. Am. Veter. Med. Assoc.* **1995**, *206*, 1737–1740.
4. Messer, N.T., 4th; Johnson, P.J. Idiopathic acute hepatic disease in horses: 12 cases (1982–1992). *J. Am. Veter. Med. Assoc.* **1994**, *204*, 1934–1937. [[PubMed](#)]
5. Aleman, M.; Nieto, J.E.; Carr, E.A.; Carlson, G.P. Serum hepatitis associated with commercial plasma transfusion in horses. *J. Veter. Intern. Med.* **2005**, *19*, 120–122. [[CrossRef](#)]
6. Chandriani, S.; Skewes-Cox, P.; Zhong, W.; Ganem, D.E.; Divers, T.J.; Van Blaricum, A.J.; Tennant, B.C.; Kistler, A.L. Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, E1407–E1415. [[CrossRef](#)]
7. Kopper, J.J.; Schott, H.C.; Divers, T.J.; Mullaney, T.; Huang, L.; Noland, E.; Smedley, R. Theiler's disease associated with administration of tetanus antitoxin contaminated with nonprimate (equine) hepacivirus and equine parvovirus-hepatitis virus. *Equine Veter. Educ.* **2018**, *32*. [[CrossRef](#)]
8. Divers, T.J.; Tennant, B.C.; Kumar, A.; McDonough, S.; Cullen, J.; Bhuva, N.; Jain, K.; Chauhan, L.S.; Scheel, T.; Lipkin, W.I.; et al. New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product. *Emerg. Infect. Dis.* **2018**, *24*, 303–310. [[CrossRef](#)]
9. Tomlinson, J.E.; Kapoor, A.; Kumar, A.; Tennant, B.C.; Laverack, M.A.; Beard, L.; Delph, K.; Davis, E.; Ii, H.S.; Lascola, K.; et al. Viral testing of 18 consecutive cases of equine serum hepatitis: A prospective study (2014–2018). *J. Veter. Intern. Med.* **2018**, *33*, 251–257. [[CrossRef](#)] [[PubMed](#)]
10. Tomlinson, J.E.; Tennant, B.C.; Struzyna, A.; Mrad, D.; Browne, N.; Whelchel, D.; Johnson, P.J.; Jamieson, C.; Löhr, C.V.; Bildfell, R.; et al. Viral testing of 10 cases of Theiler's disease and 37 in-contact horses in the absence of equine biologic product administration: A prospective study (2014–2018). *J. Veter. Intern. Med.* **2018**, *33*, 258–265. [[CrossRef](#)] [[PubMed](#)]
11. Ramsauer, A.S.; Badenhorst, M.; Cavalleri, J.V. Equine parvovirus hepatitis. *Equine Veter. J.* **2021**. [[CrossRef](#)]
12. Baird, J.; Tegtmeyer, B.; Arroyo, L.; Stang, A.; Brüggemann, Y.; Hazlett, M.; Steinmann, E. The association of Equine Parvovirus-Hepatitis (EqPV-H) with cases of non-biologic-associated Theiler's disease on a farm in Ontario, Canada. *Veter. Microbiol.* **2020**, *242*, 108575. [[CrossRef](#)]
13. Vengust, M.; Jager, M.C.; Zalig, V.; Cociancich, V.; Laverack, M.; Renshaw, R.W.; Dubovi, E.; Tomlinson, J.E.; Van de Walle, G.R.; Divers, T.J. First report of equine parvovirus-hepatitis-associated Theiler's disease in Europe. *Equine Veter. J.* **2020**, *52*, 841–847. [[CrossRef](#)] [[PubMed](#)]
14. Lu, G.; Sun, L.; Ou, J.; Xu, H.; Wu, L.; Li, S. Identification and genetic characterization of a novel parvovirus associated with serum hepatitis in horses in China. *Emerg. Microbes Infect.* **2018**, *7*, 1–7. [[CrossRef](#)] [[PubMed](#)]
15. Badenhorst, M.; de Heus, P.; Auer, A.; Tegtmeyer, B.; Stang, A.; Dimmel, K.; Tichy, A.; Kubacki, J.; Bachofen, C.; Steinmann, E.; et al. Active equine parvovirus-hepatitis infection is most frequently detected in Austrian horses of advanced age. *Equine Veter. J.* **2021**. [[CrossRef](#)]
16. Altan, E.; Li, Y.; Jr, G.S.-S.; Sawaswong, V.; Barnum, S.; Pusterla, N.; Deng, X.; Delwart, E. Viruses in Horses with Neurologic and Respiratory Diseases. *Viruses* **2019**, *11*, 942. [[CrossRef](#)] [[PubMed](#)]
17. Meister, T.L.; Tegtmeyer, B.; Brüggemann, Y.; Sieme, H.; Feige, K.; Todt, D.; Stang, A.; Cavalleri, J.-M.; Steinmann, E. Characterization of Equine Parvovirus in Thoroughbred Breeding Horses from Germany. *Viruses* **2019**, *11*, 965. [[CrossRef](#)]
18. Lu, G.; Wu, L.; Ou, J.; Li, S. Equine Parvovirus-Hepatitis in China: Characterization of Its Genetic Diversity and Evidence for Natural Recombination Events Between the Chinese and American Strains. *Front. Veter. Sci.* **2020**, *7*. [[CrossRef](#)]
19. Tomlinson, J.; Jager, M.; Struzyna, A.; Laverack, M.; Fortier, L.A.; Dubovi, E.; Foil, L.D.; Burbelo, P.D.; Divers, T.J.; Van De Walle, G.R. Tropism, pathology, and transmission of equine parvovirus-hepatitis. *Emerg. Microbes Infect.* **2020**, *9*, 651–663. [[CrossRef](#)]
20. Zdobnov, E.M.; Tegenfeldt, F.; Kuznetsov, D.; Waterhouse, R.M.; Simão, F.A.; Ioannidis, P.; Seppey, M.; Loetscher, A.; Kriventseva, E.V. OrthoDB v9.1: Cataloging evolutionary and functional annotations for animal, fungal, plant, archaeal, bacterial and viral orthologs. *Nucleic Acids Res.* **2016**, *45*, D744–D749. [[CrossRef](#)]
21. Lanini, S.; Ustianowski, A.; Pisapia, R.; Zumla, P.S.A.; Ippolito, G. Viral Hepatitis. *Infect. Dis. Clin. N. Am.* **2019**, *33*, 1045–1062. [[CrossRef](#)]
22. Kwong, S.; Meyerson, C.; Zheng, W.; Kassardjian, A.; Stanzone, N.; Zhang, K.; Wang, H.L. Acute hepatitis and acute liver failure: Pathologic diagnosis and differential diagnosis. *Semin. Diagn. Pathol.* **2019**, *36*, 404–414. [[CrossRef](#)]
23. Klastersky, J.; Aoun, M. Opportunistic infections in patients with cancer. *Ann. Oncol.* **2004**, *15*, iv329–iv335. [[CrossRef](#)] [[PubMed](#)]
24. Allen, B.M.; Hiam, K.J.; Burnett, C.E.; Venida, A.; Debarge, R.; Tenvooren, I.; Marquez, D.M.; Cho, N.W.; Carmi, Y.; Spitzer, M.H. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. *Nat. Med.* **2020**, *26*, 1125–1134. [[CrossRef](#)] [[PubMed](#)]
25. Ringelhan, M.; McKeating, J.; Protzer, U. Viral hepatitis and liver cancer. *Philos. Trans. R. Soc. B Biol. Sci.* **2017**, *372*, 20160274. [[CrossRef](#)]

26. Corcioli, F.; Zakrzewska, K.; Rinieri, A.; Fanci, R.; Innocenti, M.; Civinini, R.; de Giorgi, V.; Di Lollo, S.; Azzi, A. Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. *J. Med. Virol.* **2008**, *80*, 2005–2011. [[CrossRef](#)]
27. Söderlund-Venermo, M.; Hokynar, K.; Nieminen, J.; Rautakorpi, H.; Hedman, K. Persistence of human parvovirus B19 in human tissues. *Pathol. Biol.* **2002**, *50*, 307–316. [[CrossRef](#)]
28. Norja, P.; Hokynar, K.; Aaltonen, L.-M.; Chen, R.; Ranki, A.; Partio, E.K.; Kiviluoto, O.; Davidkin, I.; Leivo, T.; Eis-Hübinger, A.M.; et al. Bioportfolio: Lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 7450–7453. [[CrossRef](#)]

3. Diskussion

Im Rahmen dieser Doktorarbeit wurden histopathologisch veränderte Lebern von Pferden und Eseln auf das Vorhandensein von EqPV-H untersucht um Rückschlüsse auf dessen Einfluss auf unterschiedliche Lebererkrankungen abgesehen von der Theiler's Disease ziehen zu können.

Kürzlich zeigten mehrere Studien, dass EqPV-H an der Pathogenese der Theiler's Disease beteiligt ist (Divers et al. 2018; Kopper et al. 2020; Tomlinson et al. 2019a; Tomlinson et al. 2019b; Vengust et al. 2020), jedoch wurde das Virus noch nicht im Zusammenhang mit anderen Lebererkrankungen bei Equiden nachgewiesen. Auch in der Humanmedizin sind Virusinfektionen häufig ursächlich für die Entstehung von Hepatitiden und können zum Ausbruch unterschiedlicher Lebererkrankungen führen. Zu den hepatotropen Viren zählen hier das Hepatitis A, B, C, D und E Virus, aber auch nicht hepatotrope Viren wie das Adenovirus, Cytomegalievirus und Herpes Simplex Virus können zu einer akuten Hepatitis mit Leberversagen führen (Kwong et al. 2019; Lanini et al. 2019).

Je nach auslösendem Agens kommt es zu unterschiedlichen Schweregraden der Erkrankung, zu den histopathologischen Veränderungen zählen Anzeichen einer akuten oder chronischen Hepatitis, Leberzirrhose, Leberstauung aber auch die Entstehung von hepatozellulären Karzinomen (Kwong et al. 2019; Lanini et al. 2019).

In der vorgelegten Studie wurden 8 unauffällige Pferdelebern sowie 84 Lebern von Pferden und Eseln mit unterschiedlichen Hepatopathien auf das Vorhandensein von EqPV-H untersucht. In zwei von 92 Formalin-fixierten in Paraffin eingebetteten (FFPE) Leberproben konnte virale EqPV-H-DNA nachgewiesen werden. Die beiden positiv getesteten Lebern stammten von Pferden mit abdominalen Tumorerkrankungen und Metastasen in der Leber. Daraus resultiert die Frage nach einem Zusammenhang zwischen einer sekundären Infektion mit EqPV-H und Tumorerkrankungen, welche möglicherweise durch die Immunsuppression und allgemeinen Schwäche, welche mit diesen einhergeht, begünstigt werden könnte. In der Humanmedizin konnte bereits nachgewiesen werden, dass Krebspatienten ein erhöhtes Risiko für opportunistische Infektionen haben (Klastersky und Aoun 2004). Studien an Mäusen erbrachten Evidenz für eine Störung der Immunantwort bei unterschiedlichen Tumorarten mit einer verminderten T-Zell Aktivierung während viraler oder bakterieller Infektionen (Allen et al. 2020). Dies führt zur Vermutung, dass tumorerkrankte Equiden einerseits anfälliger für eine Infektion mit EqPV-H sein könnten und andererseits eine Persistenz des Virus durch eine ungenügende Immunabwehr zusätzlich begünstigt wird. Ob EqPV-H tatsächlich an der

Entstehung von primären Lebertumoren bei Equiden beteiligt ist, wurde in der vorgelegten Studie nicht untersucht, sollte jedoch Fokus zukünftiger Forschungsarbeiten sein. Zu der Gruppe der neoplastischen Erkrankungen in unserer Studie zählten nur zwei primäre Lebertumoren (Adenokarzinom der Gallengänge), in welchen jedoch keine EqPV-H DNA nachgewiesen werden konnte.

Die beiden EqPV-H positiven Lebern stammten von Pferden, welche an sekundären Leberneoplasien erkrankt waren. Bei Fall #1 wurde ein duktales Adenokarzinom mit Metastasen in multiplen abdominalen Organen, unter anderem der Leber, diagnostiziert. Die Leberenzyme im Blut lagen innerhalb der Referenzbereiche, weshalb eine akute EqPV-H-Infektion unwahrscheinlich war. Eine niedrige Anzahl an viraler DNA konnte auch im Milzgewebe festgestellt werden, wo ebenfalls Tumormetastasen vorhanden waren, sowie in Herz- und Lungengewebe.

Auch die Studie von Tomlinson et al. (2020) konnte EqPV-H DNA in verschiedenen Geweben wie Lunge, Niere, Milz, Herz und Darm zusätzlich zur Leber nachweisen. Aber auch hier zeigte sich, ähnlich wie in unserer Studie, dass die höchste Virusmenge in der Leber vorhanden war (Tomlinson et al. 2020). Eine Persistenz des Virus gilt als wahrscheinlich, da EqPV-H sogar 15 Wochen nach experimentellen Infektionen in verschiedenen Organen und im Serum nachweisbar war (Tomlinson et al. 2020). Auch das humane Parvovirus B19 kann nach einer Infektion bis zu mehrere Jahre im Serum persistieren (Corcioli et al. 2008; Norja et al. 2006; Söderlund-Venermo et al. 2002). Mit unserer Studie unterstützen wir die Vermutung einer möglichen Persistenz von EqPV-H in der Leber und anderen Organen, da eine akute Hepatitis aufgrund des klinischen Bildes, der labordiagnostischen Befunde sowie der histologischen Untersuchung nicht nachgewiesen werden konnte. Eine vorangegangene Hepatitis vor dem Klinikaufenthalt kann jedoch nicht ausgeschlossen werden.

Fall #2 wurde aufgrund erhöhter Leberenzyme sowie Gewichtsverlust an die Pferdeklinik der Vetmeduni Vienna überwiesen und nach allen Untersuchungen aufgrund des Verdachtes auf eine intraabdominale Neoplasie euthanasiert. Histologisch zeigte sich ein metastasierender perivaskulärer Gefäßwandtumor mit vermutetem Ursprung in der glatten Muskulatur der Kolonwand. Neoplastische Zellen hatten auch die Leber infiltriert und multiple Metastasen gebildet. Zur Untersuchung auf das Vorhandensein von EqPV-H-DNA standen Gewebeproben von Leber und Kolon zur Verfügung, das Virus konnte nur in der Leber nachgewiesen werden. Die erhöhte Aktivität an leberspezifischen Enzymen in diesem Patienten lassen sich durch die Infiltration des Lebergewebes mit neoplastischen Zellen und einer damit einhergehenden Schädigung sowie Zellunterganges des Parenchyms erklären. Histopathologisch konnten keine Anzeichen einer akuten Entzündungsreaktion gesehen werden. Auch in diesem Fall

scheint eine chronische Infektion oder eine Persistenz des Virus im Lebergewebe wahrscheinlich, da es pathohistologisch keine Anzeichen für eine akute Hepatitis gab.

In einer kürzlich publizierten Studie konnte eine Viruslast von $1,26 \times 10^4$ Genom Äquivalenten (GE) pro Millionen Zellen bis $2,04 \times 10^9$ GE/Millionen Zellen aus FFPE Leberproben von vier Pferden, welche an der Theiler's Disease erkrankt waren, nachgewiesen werden (Vengust et al. 2020). Die Diagnosefindung stützte sich hier auf die klinischen Anzeichen, Veränderungen der Blutchemie und histopathologische Auffälligkeiten (Vengust et al. 2020).

In unserer Studie hatten die beiden positiven Lebern eine Viruslast von 5×10^3 und $9,5 \times 10^3$ GE/Millionen Zellen, somit also etwas geringer als die kürzlich beschriebene Viruslast bei akut infizierten Pferden (Vengust et al. 2020). Dies könnte wiederum ein möglicher Hinweis auf das Vorhandensein einer chronischen Infektion sein. Auch Tomlinson et al. (2020) detektierte eine Viruslast von 1×10^4 bis 1×10^5 GE/Millionen Zellen im Lebergewebe von experimentell infizierten Pferden fünf Wochen nach Infektion. Eine Virämie konnte 2,3 Wochen nach Inokulation des Virus nachgewiesen werden (Tomlinson et al. 2020). Nach 6,5 Wochen hatten 8/10 in der Studie eingeschlossenen Pferde eine Hepatitis entwickelt, welche durch den Anstieg mindestens zweier Leberenzyme über den Referenzbereich definiert wurde (Tomlinson et al. 2020). Eines der Pferde entwickelte zusätzlich klinische Anzeichen einer Hepatitis mit Ikterus, Lethargie und Inappetenz. Da selbst 15 Wochen nach der experimentellen Infektion eine Viruslast von 1×10^1 bis 1×10^5 GE/Millionen Zellen in den Lebern der infizierten Pferde nachgewiesen werden konnten, spricht dies für eine chronischen Infektion mit Persistenz des Virus (Tomlinson et al. 2020), wie es auch in unseren beiden Fällen vermutet wurde, in denen ähnlich niedrige Viruslasten gefunden wurden.

Limitiert wurde unsere Studie durch die Lagerung der Gewebeproben, welche die Analyse bezüglich der Viruslasten eventuell beeinflusst haben könnte. Nachdem es sich hierbei um eine retrospektive Forschungsarbeit handelte, wurden die FFPE Leberproben über einen Zeitraum von einem bis 17 Jahren bei Raumtemperatur gelagert, was möglicherweise zu einer Beeinträchtigung der Anzahl an viralen Genomkopien geführt haben könnte. Die beiden positiven Lebern stammten beide von Pferden, welche im Jahr 2018 an der Pferdeklinik der Vetmeduni Vienna euthanasiert wurden und bis zur Analyse im Jahr 2020 zwei Jahre lang gelagert wurden. Trotz des möglichen Einflusses der Lagerung auf die Anzahl der nachweisbaren Virus-DNA konnte in diesen zwei Proben erfolgreich EqPV-H-DNA mittels des neu entwickelten real-time PCR Assays nachgewiesen werden, die Viruslast konnte anschließend mit digitaler PCR quantifiziert werden.

Wie bereits erwähnt, wurden beide positiven Fälle im Jahr 2018 mit nur einem Monat Abstand an der Klinik vorstellig. Eine Infektion während des Klinikaufenthaltes erscheint jedoch unwahrscheinlich, da die Inkubationszeit vermutlich zwischen 4 und 13 Wochen liegt und beide

Patienten kurze Zeit nach Aufnahme an der Klinik euthanasiert wurden (Fall #1 nach 3 Tagen, Fall #2 am Tag der Aufnahme). Ein saisonales Auftreten von EqPV-H assoziierter Theiler's Disease im Spätsommer und zu Herbstbeginn wurde bereits beschrieben (Baird et al. 2020; Tomlinson et al. 2019b; Vengust et al. 2020), der exakte Infektionszeitpunkt kann jedoch in den beiden positiv getesteten Fällen retrospektiv nicht mehr ermittelt werden. Die EqPV-H-DNA-Prävalenz liegt in den Seren gesunder österreichischer Pferde bei 8,9% (Badenhorst et al. 2021) und somit in einem ähnlichen Bereich wie in anderen Ländern (Altan et al. 2019; Divers et al. 2018; Lee et al. 2021; Lu et al. 2018; Lu et al. 2020; Meister et al. 2019b; Moraes et al. 2021), es besteht somit kein wesentlich erhöhtes Risiko einer Infektion für die österreichische Pferdepopulation.

Obwohl diese Studie durch die Anzahl an positiv getesteten Leberproben sowie aufgrund ihres retrospektiven Designs gewisse Limitationen mit sich bringt, konnten die Ergebnisse zeigen, dass EqPV-H keinen wesentlichen Einfluss auf andere Hepatopathien abgesehen von der Theiler's Disease zu haben scheint, da in 82 von 84 histopathologisch veränderten Lebern keine EqPV-H-DNA detektiert werden konnte. Dennoch ist die Entdeckung, dass beide positiv getesteten Lebern von Pferden stammten, welche mit intraabdominalen Neoplasien diagnostiziert wurden, interessant und sollte in zukünftigen Forschungsprojekten näher untersucht werden, um herauszufinden, ob es einen möglichen Zusammenhang zwischen EqPV-H-Infektionen und dem Auftreten von neoplastischen Erkrankungen gibt.

4. Zusammenfassung

Das 2018 erstmals isolierte equine Parvovirus-Hepatitis (EqPV-H) steht im Zusammenhang mit dem Ausbruch der potenziell tödlich verlaufenden Theiler's Disease, einer Erkrankung, welche zu einer akuten Hepatitis führt, welche in einem Leberversagen enden kann. EqPV-H konnte aus Serum- und Leberproben erkrankter und experimentell infizierter Pferde isoliert werden und wird im Blut gesunder subklinisch infizierter Pferde detektiert.

Ob EqPV-H auch im Zusammenhang mit anderen Lebererkrankungen beim Pferd steht, sollte mit dieser Forschungsarbeit beantwortet werden.

Das Ziel dieser retrospektiven Studie war es, Leberproben von Pferden und Eseln mit histopathologischen Veränderungen auf das Vorhandensein von EqPV-H zu untersuchen und die Viruslast mittels Quantifizierung zu bestimmen.

Hierfür wurden aus dem Archiv des Instituts für Pathologie Formalin-fixierte, in Paraffin eingebettete (FFPE) Lebern von Pferden und Eseln, welche in den Jahren 2003 bis 2019 an der Pferdeklinik der Vetmeduni Vienna euthanasiert wurden auf das Vorhandensein unterschiedlicher Leberpathologien überprüft.

Die in diese Studie eingeschlossenen Lebern wurden anhand ihrer histopathologischen Auffälligkeiten in folgende Gruppen eingeteilt: neoplastische (n=20) und entzündliche Lebererkrankungen (n=24), Leberzirrhose (n=5), zirkulationsbedingte Lebererkrankungen (n=4) und toxisch/ metabolische Lebererkrankungen (n=14). Jene Proben, welche histopathologische Veränderungen von mindestens zwei der genannten Gruppen aufwiesen wurden unter „multiple Erkrankungen“ zusammengefasst (n=17), womit die Anzahl aller erkrankten Lebern 84 ergibt. Weitere acht unauffällige Leberproben dienten als Kontrolle.

Nach DNA-Extraktion der FFPE Proben, wurden diese mit einem dafür speziell entwickelten Assay sowohl qualitativ als auch quantitativ mittels real-time PCR und digitaler PCR auf EqPV-H-DNA untersucht. In zwei Leberproben konnte Virus-DNA nachgewiesen werden, beide Lebern stammten von Pferden, welche mit intraabdominalen Tumoren und Lebermetastasen diagnostiziert wurden. Die Viruslast betrug 5×10^3 Genom Äquivalente (GE) pro Millionen Zellen (Probe #1) und $9,5 \times 10^3$ (Probe #2) GE/Millionen Zellen.

Die Menge an vorhandener Virus-DNA spricht für eine chronische Infektion oder eine Persistenz von EqPV-H, welche möglicherweise durch neoplastische Erkrankungen begünstigt oder sogar gefördert wird. Zusammenfassend konnte mit unserer Studie kein Nachweis erbracht werden, dass EqPV-H abgesehen von der Theiler's Disease noch mit anderen Lebererkrankungen in Verbindung steht. Dass EqPV-H ausschließlich bei zwei Pferden mit intraabdominalen Neoplasien und Lebermetastasen gefunden wurde, ist jedoch

durchaus interessant und der mögliche Einfluss des Virus auf neoplastische Erkrankungen sollte in zukünftigen Studien näher untersucht werden.

5. Summary

There is compelling evidence that EqPV-H, which was first detected in the year 2018, is associated with the onset of Theiler's disease, an acute and potentially life-threatening hepatic necrosis in horses. Since then, EqPV-H was isolated from serum and liver samples of diseased and experimentally infected horses, furthermore, it could be detected in blood samples of subclinical infected horses. However, the impact of this virus on other hepatopathies remains unknown and was the focus of this research.

The objective of this retrospective study was to evaluate the prevalence and quantify the viral loads of EqPV-H in formalin-fixed, paraffin-embedded (FFPE) equine and donkey livers with various histopathologic abnormalities. Therefore, the samples archive of the Institute of Pathology was searched for horses and donkeys that were euthanised between 2003 and 2019 at the University Equine Hospital of the Vetmeduni Vienna with various liver pathologies. The pathologies included neoplastic (n=20) and inflammatory diseases (n=24), cirrhosis (n=5), circulatory disorders of the liver (n=4) and toxic and metabolic hepatic diseases (n=14). Samples that were simultaneously diagnosed with at least two histopathologic features were assigned to the multiple disease group (n=17), leading to a total number of 84 samples. Eight normal liver samples were included for comparison as controls.

After the extraction of viral nucleic acid of the FFPE samples, EqPV-H DNA was qualitatively and quantitatively measured by real-time PCR and digital PCR using a specially designed assay. The virus was detected in two livers originating from horses diagnosed with abdominal neoplasia and liver metastasis. Viral loads were 5×10^3 genome equivalents (GE) per million cells (sample #1) and 9.5×10^3 GE/million cells (sample #2). The amount of viral nucleic acids measured indicates chronic infection or persistence of EqPV-H, which might have been facilitated by the neoplastic disease. In summary, this study did not provide evidence for EqPV-H being involved in hepatopathies other than Theiler's disease, but the fact that both positive samples originated from horses diagnosed with intraabdominal neoplasia and liver metastasis is interesting and further research on the influence of EqPV-H on neoplastic diseases may be warranted.

6. Abkürzungsverzeichnis

DNA	Desoxyribonukleinsäure
EqPV-H	Equines Parvovirus-Hepatitis
FFPE	Formalin-fixiert, in Paraffin eingebetteten
GE	Genome equivalents/ Genom Äquivalente
dPCR	digital polymerase chain reaction/ digitale Polymerase-Kettenreaktion
PCR	polymerase chain reaction/ Polymerase-Kettenreaktion

7. Literaturverzeichnis

Aleman M, Nieto JE, Carr EA, Carlson GP. 2005. Serum hepatitis associated with commercial plasma transfusion in horses. *Journal of Veterinary Internal Medicine*, 19 (1): 120–122. DOI 10.1892/0891-6640(2005)19<120:shawcp>2.0.co;2.

Allen BM, Hiam KJ, Burnett CE, Venida A, DeBarge R, Tenvooren I, Marquez DM, Cho NW, Carmi Y, Spitzer MH. 2020. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. *Nature Medicine*, 26 (7): 1125–1134. DOI 10.1038/s41591-020-0892-6.

Altan E, Li Y, Sabino-Santos G, Sawaswong V, Barnum S, Pusterla N, Deng X, Delwart E. 2019. Viruses in horses with neurologic and respiratory diseases. *Viruses*, 11 (10): 942. DOI 10.3390/v11100942.

Badenhorst M, De Heus P, Auer A, Tegtmeyer B, Stang A, Dimmel K, Tichy A, Kubacki J, Bachofen C, Steinmann E, Cavalleri JMV. 2021. Active equine parvovirus-hepatitis infection is most frequently detected in Austrian horses of advanced age. *Equine Veterinary Journal*, 54(2): 379–389. DOI 10.1111/evj.13444.

Baird J, Tegtmeyer B, Arroyo L, Stang A, Brüggemann Y, Hazlett M, Steinmann E. 2020. The association of Equine Parvovirus-Hepatitis (EqPV-H) with cases of non-biologic-associated Theiler's disease on a farm in Ontario, Canada. *Veterinary Microbiology*, 242: 108575. DOI 10.1016/j.vetmic.2019.108575.

Chandriani S, Skewes-Cox P, Zhong W, Ganem DE, Divers TJ, van Blaricum AJ, Tennant BC, Kistler AL. 2013. Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. *Proceedings of the National Academy of Sciences of the United States of America*, 110(15):E1407-E1415. DOI 10.1073/pnas.1219217110.

Corcioli F, Zakrzewska K, Rinieri A, Fanci R, Innocenti M, Civinini R, Giorgi V de, Di Lollo S, Azzi A. 2008. Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. *Journal of Medical Virology*, 80 (11): 2005–2011. DOI 10.1002/jmv.21289.

De Moraes MVDS, Salgado CRS, Godoi TLOS, De Almeida FQ, Chalhoub FLL, De Filippis AMB, De Souza AM, De Oliveira JM, Figueiredo AS. 2021. Equine parvovirus-hepatitis is detected in South America, Brazil. *Transboundary and Emerging Diseases*, 69(5): 3022-3027. DOI 10.1111/tbed.14226.

Divers TJ, Tennant BC, Kumar A, McDonough S, Cullen J, Bhuvra N, Jain K, Chauhan LS, Scheel TKH, Lipkin WI, Laverack M, Trivedi S, Srinivasa S, Beard L, Rice CM, Burbelo PD, Renshaw RW, Dubovi E, Kapoor A. 2018. New parvovirus associated with serum hepatitis in horses after inoculation of common biological product. *Emerging Infectious Diseases*, 24 (2): 303–310. DOI 10.3201/eid2402.171031.

Guglick MA, MacAllister CG, Ely RW, Edwards WC. 1995. Hepatic disease associated with administration of tetanus antitoxin in eight horses. *Journal of the American Veterinary Medical Association*, 206 (11): 1737–1740.

Hjerpe CA. 1964. Serum hepatitis in the horse. *Journal of the American Veterinary Medical Association*, 144: 734–740.

Klastersky J, Aoun M. 2004. Opportunistic infections in patients with cancer. *Annals of Oncology : Official Journal of the European Society for Medical Oncology*, 15 Suppl 4: iv329-35. DOI 10.1093/annonc/mdh947.

Kopper JJ, Schott HC, Divers TJ, Mullaney T, Huang L, Noland E, Smedley R. 2020. Theiler's disease associated with administration of tetanus antitoxin contaminated with nonprimate (equine) hepacivirus and equine parvovirus-hepatitis virus. *Equine Veterinary Education*, 32:e5-e9. DOI 10.1111/eve.12999.

Kwong S, Meyerson C, Zheng W, Kassardjian A, Stanzione N, Zhang K, Wang HL. 2019. Acute hepatitis and acute liver failure: pathologic diagnosis and differential diagnosis. *Seminars in Diagnostic Pathology*, 36 (6): 404–414. DOI 10.1053/j.semmp.2019.07.005.

Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. 2019. Viral hepatitis: etiology, epidemiology, transmission, diagnostics, treatment, and prevention. *Infectious Disease Clinics of North America*, 33 (4): 1045–1062. DOI 10.1016/j.idc.2019.08.004.

Lee S-K, Park D, Lee I. 2021. Molecular prevalence of equine parvovirus-hepatitis in the sera of clinically healthy horses in South Korea. *Veterinary Sciences*, 8 (11): 282. DOI 10.3390/vetsci8110282.

Lu G, Sun L, Ou J, Xu H, Wu L, Li S. 2018. Identification and genetic characterization of a novel parvovirus associated with serum hepatitis in horses in China. *Emerging Microbes & Infections*, 7 (1): 170. DOI 10.1038/s41426-018-0174-2.

Lu G, Wu L, Ou J, Li S. 2020. Equine parvovirus-hepatitis in China: characterization of its genetic diversity and evidence for natural recombination events between the Chinese and American strains. *Frontiers in Veterinary Science*, 7: 121. DOI 10.3389/fvets.2020.00121.

Meister TL, Tegtmeyer B, Postel A, Cavalleri J-MV, Todt D, Stang A, Steinmann E. 2019. Equine parvovirus-hepatitis frequently detectable in commercial equine serum pools. *Viruses*, 11(5): 461. DOI 10.3390/v11050461.

Meister TL, Tegtmeyer B, Brüggemann Y, Sieme H, Feige K, Todt D, Stang A, Cavalleri J-MV, Steinmann E. 2019. Characterization of equine parvovirus in thoroughbred breeding horses from Germany. *Viruses*, 11(10): 965. DOI 10.3390/v11100965

Messer NT, Johnson PJ. 1994. Serum hepatitis in two brood mares. *Journal of the American Veterinary Medical Association*, 204 (11): 1790–1792.

Messer NT, Johnson PJ. 1994. Idiopathic acute hepatic disease in horses: 12 cases (1982-1992). *Journal of the American Veterinary Medical Association*, 204 (12): 1934–1937.

Norja P, Hokynar K, Aaltonen L-M, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hübinger AM, Schneider B, Fischer H-P, Tolba R, Vapalahti O, Vaheeri A, Söderlund-Venermo M, Hedman K. 2006. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. *Proceedings of the National Academy of Sciences of the United States of America*, 103 (19): 7450–7453.
DOI 10.1073/pnas.0602259103.

Pancieria RJ. 1969. Serum hepatitis in the horse. *Journal of the American Veterinary Medical Association*, 155 (2): 408–410.

Ramsauer AS, Badenhorst M, Cavalleri J-MV. 2021. Equine parvovirus hepatitis. *Equine Veterinary Journal*, 53: 886–894. DOI 10.1111/evj.13477.

Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. 2002. Persistence of human parvovirus B19 in human tissues. *Pathologie-biologie*, 50 (5): 307–316.
DOI 10.1016/s0369-8114(02)00307-3.

Step DL, Blue JT, Dill SG. 1991. Penicillin-induced hemolytic anemia and acute hepatic failure following treatment of tetanus in a horse. *The Cornell Veterinarian*, 81 (1): 13–18.

Theiler A. 1918. Acute liver-atrophy and parenchymatous hepatitis in horses. Union of South Africa. Dept. of Agriculture. 5th and 6th Repts. of the Director of Veterinary Research.

Thomsett LR. 1971. Acute hepatic failure in the horse. *Equine Veterinary Journal*, 3 (1): 15–19. DOI 10.1111/j.2042-3306.1971.tb04433.x.

Tomlinson JE, Jager M, Struzyna A, Laverack M, Fortier LA, Dubovi E, Foil LD, Burbelo PD, Divers TJ, van de Walle GR. 2020. Tropism, pathology, and transmission of equine parvovirus-hepatitis. *Emerging Microbes & Infections*, 9 (1): 651–663.
DOI 10.1080/22221751.2020.1741326.

Tomlinson JE, Kapoor A, Kumar A, Tennant BC, Laverack MA, Beard L, Delph K, Davis E, Schott li H, Lascola K, Holbrook TC, Johnson P, Taylor SD, McKenzie E, Carter-Arnold J, Setlakwe E, Fultz L, Brakenhoff J, Ruby R, Trivedi S, van de Walle GR, Renshaw RW, Dubovi EJ, Divers TJ. 2019. Viral testing of 18 consecutive cases of equine serum hepatitis: A prospective study (2014-2018). *Journal of Veterinary Internal Medicine*, 33 (1): 251–257.
DOI 10.1111/jvim.15368.

Tomlinson JE, Tennant BC, Struzyna A, Mrad D, Browne N, Whelchel D, Johnson PJ, Jamieson C, Löhr CV, Bildfell R, McKenzie EC, Laverack M, Renshaw RW, Dubovi E, Kapoor A, Meirs RS, Belgrave R, Engiles J, van de Walle GR, Divers TJ. 2019. Viral testing of 10 cases of Theiler's disease and 37 in-contact horses in the absence of equine biologic product administration: A prospective study (2014-2018). *Journal of Veterinary Internal Medicine*, 33 (1): 258–265. DOI 10.1111/jvim.15362.

Vengust M, Jager MC, Zalig V, Cociancich V, Laverack M, Renshaw RW, Dubovi E, Tomlinson JE, van de Walle GR, Divers TJ. 2020. First report of equine parvovirus-hepatitis-associated Theiler's disease in Europe. *Equine Veterinary Journal*, 52 (6): 841–847. DOI 10.1111/evj.13254.

8. Danksagung

An dieser Stelle möchte ich mich bei allen Personen bedanken, die mich bei meiner Dissertation unterstützt haben.

Mein besonderer Dank gilt Jessica Cavalleri, die dieses Projekt erst ermöglicht und mich während der gesamten Arbeit mit viel Kompetenz und Freude betreut hat.

Großer Dank geht an Sophie Ramsauer, die mir immer mit Rat und Tat zur Seite stand, mich in allen Belangen unterstützte und ohne die die Umsetzung unserer Studie nicht möglich gewesen wäre. Vielen Dank liebe Sophie, du warst mir eine unendlich große Hilfe!

Vielen Dank an Martin Hofer, sowohl für deinen fachlichen Beitrag als auch deine unendlich scheinende Geduld mir alles zum Thema PCR; Statistik und Rechenmethoden zu erklären.

Außerdem möchte ich mich bei Ralf Steinborn für seine Unterstützung und seinen wissenschaftlichen Beitrag zu unserer Publikation bedanken.

Herzlichen Dank auch an Andrea Klang für die histologische Befundung der Leberproben sowie ihre Unterstützung bei unserer Publikation.

Vielen Dank an Irina Preining für die kurzfristige Hilfe bei der Auswertung unserer Daten.

Ein herzliches Dankeschön möchte ich auch an Herbert Weissenböck, Christiane Weissenbacher-Lang sowie an alle beteiligten Personen des Instituts für Pathologie für eure freundliche und kompetente Unterstützung zur Umsetzung dieses Projektes aussprechen.

Vielen Dank auch an das gesamte Team der Abteilung für Interne Medizin Pferde für die schönen letzten Jahre. Ich habe so viel von euch lernen dürfen und dafür bin ich sehr dankbar!

Für die finanzielle Unterstützung für die Umsetzung dieses Projektes möchte ich mich bei der Schweizer Stiftung „Pro Pferd“ bedanken.

Mein größter Dank gilt meiner Familie und meinen Freunden. Ihr habt mich auch in schwierigen Zeiten immer unterstützt, aufgeheitert und ermutigt niemals aufzugeben. Ohne eure Hilfe und Unterstützung wäre ich nicht da, wo ich jetzt bin. Danke!